Abstract: Objective To evaluate the efficacy of ornithine aspartate in the treatment of patients with fatty liver. Methods According to the inclusion and exclusion criteria,China National Knowledge Infrastructure（CNKI）,Wanfang database,PubMed,EMBASE and Cochrane library up to July 20,2017 were screened for randomized controlled trial of ornithine aspartate in the treatment of patients with fatty liver. The Cochrane handbook was used to assess the risk bias,and the Jadad 7 subscales was used to document the quality score. Meta analysis by using RevMan 5.3 was made. Results A total of 727 Chinese patients with fatty liver were enrolled in the 9 Chinese clinical trials. The results of Meta analysis showed that total clinical efficiency rate in L-ornithine-L-aspartate treatment was much higher as compared to that in the control[OR=3.71,95%CI（1.85,7.46）,P=0.0002];the decreased serum total cholesterol level was[MD=-3.04,95%CI（-3.76,-2.31）,P<0.00001],and the decreased serum triglyceride level was[MD=-1.60,95%CI（-2.55,-0.65）,P=0.0009]; the total effective rate in L-ornithine-L-aspartate treatment was[OR=11.99,95%CI（2.36,60.91）,P=0.003];the decreased serum ALT was [MD=-34.04,95%CI（-61.73,-6.35）,P=0.02], and the decreased serum AST level was[MD=-9.48, 95%CI（-24.66,5.70）,P=0.22];the decrease total serum bilirubin was[MD=-14.92,95%CI（-20.70,-9.15）,P<0.00001]. Conclusion The application of L-ornithine-L-aspartate in the treatment of patients with fatty liver has a better therapeutic effect,which might improve the indexes of liver function and blood lipids. The efficacy of L-ornithine L-aspartate in the treatment of patients with fatty liver needs to be confirmed by multi-center,well-designed randomized clinical trials in the future.

Key words: Fatty liver diseases, L-ornithine-L- aspartate, Efficacy, Meta analysis